Autologous Transplantation for Chronic Myelogenous Leukemia

计划入组 24 人 · 首次发布于 2009 年 10 月 28 日

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

计划入组 23 人 · 首次发布于 2002 年 10 月 9 日

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

计划入组 6 人 · 首次发布于 2011 年 7 月 11 日

Ezh2 inhibitors (chronic myelogenous leukemia)

Busulfan(Busulfex, Myleran, Busulfan Fresenius Kabi)

<dd class="col-xl-8 col-md-9 col-sm-8">C₆H₁₄O₆S₂</dd> · Rx

acute myelogenous leukemia program

Kineta Chronic Pain LLC

United States

JAPAN ADULT LEUKEMIA STUDY GROUP

Japan

MEMORIAL SLOAN-KETTERING CANCER CENTER

United States

FDA Approves Bosutinib for Pediatric Chronic Myelogenous Leukemia Patients

ImmunoForge's Pemziviptadil Receives FDA IND Approval for Phase 2 DMD Cardiomyopathy Trial

FDA Approves Scemblix (asciminib) for First-Line Treatment of Chronic Myelogenous Leukemia